Dr. Morag Park awarded prestigious Robert L. Noble Prize
Dr. Morag Park, Professor of Biochemistry, Medicine and Oncology and Director of the Goodman Cancer Research Centre at McGill...
New marker and potential therapy for triple negative breast cancer
Triple negative breast cancer (TNBC) is the most aggressive type of breast cancer, found in 15-20% of all cases. These breast tumors are...
New marker identified for pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths. Due to its deep anatomical location, tumour-specific symptoms typically occur only...
A race against time to diagnose deadly weight loss in cancer patients
About one third of cancer patients die because of cachexia – an involuntary weight loss, characterized primarily by muscle wasting and metabolic changes, which cannot be addressed or treated solely...
A key to unlocking the mystery of triple negative breast cancer
A study conducted at the Research Institute of the McGill University Health Centre (RI-MUHC) suggests screening breast cancer patients for the prolactin receptor...
RI-MUHC researchers discover new path to stop the spread of cancer
Investigators from the Research Institute of the McGill University Health Centre (RI-MUHC), and the Institute of Cancer Research, London (UK), have discovered...
New Laval clinic aims to expand reach of MUHC DOvEE project
The DOvEE project (Diagnosing Ovarian and Endometrial Cancer Early) of the McGill University Health Centre (MUHC) has opened a satellite clinic at Place des aînés de Laval.
RI-MUHC team receives funding to develop improved radiation treatment devices for cancer patients
The Research Institute of the McGill University Health Centre (RI-MUHC) is proud to announce that Dr. Shirin Abbasinejad Enger, researcher from the Cancer Research Program...